Investor Presentation

••a PADMANABH ~[ NAVIN FLUORINE J ••" MAFATLAL International Limited GROUP August 05, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Fort, Bandra Kurla Complex, Bandra (East), Mumbai 400001 Mumbai 400051 Scrip Code: 532504 Symbol: NAVINFLUOR Dear Sir / Madam, Sub.: Investor Presentation for Q1 of Financial Year 2026-27 In accordance with Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Investor Presentation of the Company for the quarter ended June 30, 2026 (Q1 of FY 2026-27) is enclosed. This intimation is also being made available on the Company’s website www.nfil.in. Kindly take this intimation on your record. Thanking You, Yours faithfully, For NAVIN FLUORINE INTERNATIONAL LIMITED Niraj B. Mankad President Legal & Company Secretary Encl.: a/a Navin Fluorine International Limited 602, 6th Floor, Natraj By Rustomjee, M.V. Road, Western Express Highway, Near Kanakia 351 Building, Andheri (East), Mumbai 400069 India. T: +91 22 6650 9999 E: info@nfil.in W: www.nfil.in • • • CIN: L24110MH1998PLC115499 Investor Presentation 5th August 2026 Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Navin Fluorine International Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections. Q1 FY27 – Performance highlights Business Highlights SALES Operating EBITDA Rs. 1,045.1 Cr Rs. 357.1 Cr Y-O-Y REVENUE GROWTH +44% YoY +11% QoQ +73% YoY +11% QoQ HPP 33% Specialty 48% Operating EBITDA Margin Operating PBT CDMO 82% 34.2 % Rs. 283.3 Cr +566 bps YoY -8 bps QoQ +101% YoY +13% QoQ Consolidated Financials Q1 FY27 – Sustainable growth Revenues Operating EBITDA Rs. Crs Rs. Crs 1,045 758 308 Q3 FY25 Q4 FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q3 FY25 Q4 FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Operating PBT PAT Rs. Crs Rs. Crs 243 251 243 98 115 84 95 Q3 FY25 Q4 FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q3 FY25 Q4 FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Business Vertical - HPP Revenue In Rs. Crs Key Highlights +33% 540 ✓ Revenue growth led by volume and higher realisations ✓ Pricing environment for HFC continues to be constructive; increasing interest for contractual offtakes in new capacities ✓ AHF facility commenced operations in Q4 FY26 and continues to be ramped up ✓ Capex for additional HFC capacity equivalent upto 15,000 MTPA of R32 is on track to Q1FY26 Q1FY27 be commissioned in Q3FY27 GEOGRAPHIC MIX Consolidated Financials Business Vertical - Specialty Chemicals Revenue In Rs. Crs Key Highlights +48% 325 ✓ Sustained growth underpinned by strong order visibility ✓ Product pipeline continues to remain strong, with meaningful scale-up across existing molecules and a strong line-up of new launches ✓ Chemours project is targeted for completion by end of Q2 FY27 ✓ De-bottlenecking MPP capacity at Dahej is on track for commissioning in Q3 FY27 Q1FY26 Q1FY27 GEOGRAPHIC MIX Consolidated Financials Business Vertical - CDMO Revenue In Rs. Crs Key Highlights +82% ✓ Strong momentum continues, backed by order book ✓ Continued deeper engagement with European CDMO major. Supported by: • Increasing demand for existing molecule • Expanding our footprint in their supply chain ✓ Board had already approved cGMP4 capex of Rs. 288 Crs in Feb 24 Q1FY26 Q1FY27 • Phase I capex operationalized in Q3 FY26. Initiated today, Phase II - cGMP4 capex GEOGRAPHIC MIX of Rs. 125 Crs is expected to operationalize by Q4 FY27 ✓ Strategy -in-action : • Balanced portfolio with good mix of late/commercial and early-stage molecules • Increasing footprint across range of promising therapeutic areas with global innovators- Oncology, Respiratory, Cardiovascular, Neurology and Animal health Consolidated Financials Incubating advanced materials Putting our strategy into action for developing a new high growth, high margin business vertical for the future. Building on core fluorination capabilities, the vertical will focus on niche applications in high growth sunrise sector – Data Centers, Electronics, Defence & Semiconductors. ADOPTION CAPACITIES Setting up adoption capacities to commercialise product pipeline. Capex : Rs. 90 Crs CHEMOURS PROJECT Setting up Initial commercial capacity to enable adoption of innovative liquid cooling product Capex : Rs. 120 Crs Driving AtmaNirbhar Bharat through DRDO TDF DRDO project for indigenous process development for a critical defence material New capex Advanced Materials cGMP4* To set up adoption capacities for Initiated today, Phase II - cGMP4 capex of Capex Details Advanced Materials Rs. 125 Crs • Incubate new value accretive business • Increasing demand for existing vertical as a future growth driver molecule of European CDMO major. Capex Rational • Expanding our footprint in their supply • Augment capability and cater to chain commercial scale qualification supplies Amount & • Capex of Rs. 90 Crs • Capex cost of phase II - Rs.125 Crs Completion • Completion by Q2 FY28 • Completion by Q4 FY27 Date Peak Revenue Access future growth opportunity An asset turnover of ~3x Potential * Board had already approved cGMP4 capex of Rs. 288 Crs in Feb 24 Ongoing capex program HFC MPP Chemours Project Renewable power project Additional HFC capacity De-bottlenecking MPP Initial commercial capacity Investment in SPV for setting Capex equivalent upto 15,000 MTPA capacity at Dahej to support for manufacturing to enable up of hybrid power plant Details of R32 launch of new molecule for a adoption of innovative liquid global innovator cooling product • Reinforces sustainability Co [Showing first 8,000 characters — download PDF for full document]